Aeglea Biotherapeutics Inc. (NASDAQ:AGLE)’s share price was up 7.5% during mid-day trading on Tuesday . The company traded as high as $5.17 and last traded at $5.04, with a volume of 223,675 shares. The stock had previously closed at $4.69.

A number of equities analysts have issued reports on AGLE shares. Needham & Company LLC began coverage on Aeglea Biotherapeutics in a research report on Monday, May 9th. They set a “buy” rating and a $18.00 price target on the stock. BMO Capital Markets began coverage on Aeglea Biotherapeutics in a research report on Monday, May 2nd. They issued an “outperform” rating and a $19.00 target price on the stock. Wells Fargo & Co. began coverage on Aeglea Biotherapeutics in a research report on Monday, May 2nd. They issued an “outperform” rating on the stock. Finally, Zacks Investment Research downgraded Aeglea Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 11th.

The stock’s market cap is $68.80 million. The firm’s 50-day moving average is $4.66 and its 200-day moving average is $6.62.

Aeglea Biotherapeutics (NASDAQ:AGLE) last posted its earnings results on Tuesday, August 9th. The company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.03. Analysts expect that Aeglea Biotherapeutics Inc. will post ($4.53) EPS for the current year.

Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.